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REGIMEN DURABILITY IN HIV-POSITIVE CHILDREN 
 
AND ADOLESCENTS INITIATING FIRST-LINE ART IN A 
 
LARGE PUBLIC SECTOR HIV COHORT IN SOUTH AFRICA 
 
RACHAEL BONAWITZ 
ABSTRACT 
Introduction: In April 2010 tenofovir and abacavir replaced stavudine in public-sector 
first-line antiretroviral therapy (ART) for children under 20 years old in South Africa. 
The association of both abacavir and tenofovir with fewer side-effects and toxicities 
compared to stavudine could translate to increased durability of tenofovir or abacavir-
based regimens. We evaluated changes over time in regimen durability for pediatric 
patients 3 to 19 years of age at 8 public sector clinics in Johannesburg, South Africa.  
Methods: Cohort analysis of treatment naïve, non-pregnant pediatric patients from 3 to 
19 years old initiated on ART between April 2004-December 2013. First-line ART 
regimens before April 2010 consisted of stavudine or zidovudine with lamivudine and 
either efavirenz or nevirapine. Tenofovir and/or abacavir was substituted for stavudine 
after April 2010 in first-line ART. We evaluated the frequency and type of single-drug 
substitutions, treatment interruptions, and switches to second-line therapy. Fine and Gray 
competing risk regression models were used to evaluate the association of antiretroviral 
drug type with single-drug substitutions, treatment interruptions, and second-line 
switches in the first 24-months on treatment. 
Results: 398 (15.3%) single-drug substitutions, 187 (7.2%) treatment interruptions and 
86 (3.3%) switches to second-line therapy occurred among 2602 pediatric patients over 
  vi 
24-months on ART. Overall, the rate of single-drug substitutions started to increase in 
2009, peaked in 2011 at 25%, then declined to 10% in 2013, well after the integration of 
tenofovir into pediatric regimens; no patients over the age of 3 were initiated on abacavir 
for first-line therapy. Competing risk regression models showed patients on zidovudine or 
stavudine had upwards of a 5-fold increase in single-drug substitution vs. patients 
initiated on tenofovir in the first 24-months on ART. Older adolescents also had a 2-3-
fold increase in treatment interruptions and switches to second-line therapy compared to 
younger patients in the first 24-months on ART.  
Conclusions: The decline in single-drug substitutions is associated with introduction of 
tenofovir. Tenofovir use could improve regimen durability and treatment outcomes in 
resource-limited settings.  
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CHAPTER ONE: INTRODUCTION 
 In 2015, there were an estimated 1.8 million children under age 15 living with 
HIV globally, with 150,000 new pediatric infections annually (1). Despite prevention of 
mother to child transmission (PMTCT) programs, large numbers of children are still 
perinatally infected. In South Africa, approximately 370,000 children under age 15 are 
currently living with HIV, and in 2012, there were an estimated 166,000 children 
receiving antiretroviral therapy (ART) (2). As the pediatric ART program has matured, 
numerous changes were made to South African national guidelines regarding first-line 
ART for pediatric patients. Prior to 2010, standard first-line ART for children under age 3 
included a protease-inhibitor and two nucleoside reverse transcriptase inhibitors (NRTIs); 
after age 3, children were transitioned to a non-nucleoside reverse transcriptase inhibitor 
(NNRTI) backbone regimen. In 2010, the South African National Guidelines 
recommended either abacavir or tenofovir for children under 14, and tenofovir for 
adolescents over 14, as preferential NRTIs over stavudine for initiation regimens (3, 4) in 
accordance with World Health Organization (WHO) guidelines (5, 6) (Table 1).  
 Regimen durability, defined as the time from initiation of an ART regimen until 
first modification of that regimen, is a crucial aspect of pediatric HIV treatment given the 
necessity of conserving ART regimens for a lifetime. Pediatric first-line regimens may be 
affected by single-drug substitutions, treatment interruptions, or switches to second-line 
therapy. There have been limited data from LMICs regarding regimen durability for 
pediatric patients. Previous data from a single pediatric ART facility in South Africa 
showed that 83% of pediatric patients remained in care over four years, 65% stayed on 
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their initiating regimen, and 26% had a single-drug substitution for ART-related toxicities 
(7).  This evidence from a single pediatric site was published prior to the 2010 South 
African guidelines change. More recent data from two pediatric programs in South Africa 
post-2010 have shown that 26% of children remained on their initial regimen over 5 
years, with toxicity to stavudine being the most common reason for discontinuation (8).  
 Preservation of ART regimens in the pediatric population is essential for children 
who will survive to adulthood and require ART for many years. Because HIV-infected 
children must have good adherence to ART, better understanding of factors associated 
with regimen instability is needed to strengthen pediatric ART programs and ensure 
survival of successive generations of children. Research on adult patients in LMICs has 
demonstrated a decline in single-drug substitutions in the first 12 months on ART with 
the introduction of tenofovir after 2010 (9-15). However, large-scale examinations of 
ART regimen durability in children in light of changing guidelines, with respect to the 
inclusion of both tenofovir and abacavir replacing stavudine for pediatric patients, is 
needed. We sought to assess the association of first-line NRTI and regimen durability in a 
large pediatric cohort in South Africa.  
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Age group (years) Pre 2010 Post 2010 
3 to 5  d4T + 3TC + EFV  ABC + 3TC + EFV 
TDF + 3TC + EFV 
 
5 to <14  
 
d4T + 3TC + EFV 
  
ABC + 3TC + EFV 
 
 
14 to <20  
 
 
d4T + 3TC + EFV 
d4T + 3TC + NVP 
AZT + 3TC + 
EFV 
AZT + 3TC + 
NVP 
 
 
 
 
TDF + 3TC + EFV 
 
TDF + 3TC + EFV 
TDF + 3TC + NVP 
 
 
Table 1. 2004 and 2010 South African National Treatment Guidelines for first-line ART for 
children and adolescent HIV-positive patients  
*Table adapted from South African National Antiretroviral Treatment Guidelines 20042 and 20103 
d4T, stavudine; 3TC, lamivudine; EFV, efavirenz; NVP, nevirapine; AZT, zidovudine; ABC, 
abacavir; TDF tenofovir
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CHAPTER TWO: METHODS 
Cohort description 
 This was an analysis of prospectively collected cohort data. Patients included in 
the cohort are ages 3 to 19 years old initiating antiretroviral (ARV) drugs at one of eight 
HIV clinics in Gauteng and Mpumalanga provinces, South Africa (16). These are primary 
healthcare sites, supported by Right to Care, a South African non-governmental 
organization funded by the Unites States Agency for International Development (USAID) 
(16).  All clinical data are entered into an electronic clinical database (TherapyEdge-
HIV™) in real-time by either a clinician or data entry clerk at the clinic. Since the wide-
scale rollout of ART in April 2004, clinic staff at these eight sites have provided pediatric 
HIV care according to South African National Department of Health Guidelines (3-5).  
 Standard first-line ART prior to April 2010 for children 3-14 years old was 
stavudine, lamivudine, and efavirenz. First-line ART for adolescents >14 years old 
included lamivudine, and the second NRTI was either stavudine or zidovudine, with 
either efavirenz or nevirapine for NNRTI. After 2010, the South African National 
Guidelines recommended either abacavir or tenofovir for children 3-14 years old, or only 
tenofovir for adolescents >14 years old, as the preferential NRTIs in first-line ART (3-5) 
(Table 1).  
 Routine laboratory tests (CD4 counts, hemoglobin, liver function tests, creatinine 
clearance), with exception of HIV viral load, are conducted at the time of ART initiation.  
Additional testing (TB microscopy and culture results, lactate levels, glucose, lipid 
profiles) is performed when clinically indicated. Prior to 2010, CD4 counts and viral 
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loads were repeated at three and six months post-initiation and then every six months, but 
the 2010 guidelines recommended them at 6 and 12 months after initiation and then 
yearly thereafter (4,5).  
Eligibility Criteria:  
 All non-pregnant, ART-naïve patients over 3 years of age and younger than 20 
years of age initiating a standard public-sector first-line ART regimen at one of these 
eight clinics between April 2004 and December 2013 were included in this analysis. All 
patients had the potential for 24-months of follow-up.  
Study Variables:   
 Primary outcomes for this analysis were: (1) single-drug substitutions, defined as 
changing the NRTI only, excluding lamivudine, within first-line ART; (2) treatment 
interruptions, defined as stopping ART for at least one week before resuming a regimen; 
and (3) switch to second-line therapy, defined as a new NRTI substitution and 
replacement of the NNRTI for a protease inhibitor. All outcomes were measured in the 
first 24-months on ART. Loss to follow-up is defined as loss to follow-up 3 months after 
last-scheduled visit (4 months from last actual clinic visit).  All outcomes were calculated 
individually.  
Statistical Analysis:  
 Patient baseline characteristics were summarized with simple descriptive statistics 
and stratified by year of ART initiation. Three separate models were run. For each model, 
person-time began at ART initiation and ended at the earliest of: (1) primary outcome of 
interest (i.e. single-drug substitution (model 1), treatment interruption (model 2), and 
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second-line switch (model 3)); (2) loss to follow-up; (3) death; (4) transfer; (5) 
completion of 24 months of follow-up. Fine and Gray’s competing risks regression 
method (17) was used to evaluate association of type of NRTI in first-line regimen on 
primary outcomes of interest: single-drug substitution, treatment interruption and second-
line switch, accounting for attrition as a competing risk. Models were adjusted for age 
(categorized as 3-4.9, 5-9.9, 10-13.9 and 14-19.9 years of age) and gender, and CD4 
count (categorized as <50, 51-100, 101-200, 201-350 and >350 cell/mm3), hemoglobin 
levels (<10ug/dl vs. >10 ug/dL), WHO stage (18) and body mass index at ART initiation 
(19). Analyses were performed using the SAS 9.3 statistical software package (SAS 
Institute, INC., Cary NC).  
Interaction:  
 The interaction between gender and NRTI and age and NRTI was assessed on the 
additive scale by calculating the risk due to interdependence (R(I))(20).  
Ethical Review: 
 Approval for analysis of de-identified data was granted by the Institutional 
Review Board of Boston University and the Human Research Ethics Committee of the 
University of Witwatersrand.  
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CHAPTER THREE: RESULTS 
 In total, 2602 treatment-naïve, non-pregnant children between 3 and 19 years of 
age initiated a first-line ART regimen between April 2004 and December 2013 (Table 2). 
Demographic and clinical characteristics were similar across clinics. Patients were 
predominately female (55.7%) with median age of 10.4 years (interquartile range (IQR): 
6.1-14.5), predominately on first-line regimen of stavudine/lamivudine/efavirenz (78.9%) 
with median time on treatment of 23.4 months (IQR: 12.6-24.0). At ART initiation, 
patients had a median CD4 count of 317 cells/mm3 (IQR: 85-417). Over 24 months of 
follow-up, a total of 132 (5.1%; 95% CI: 4.3-6.0%) children died, 799 (30.7%; 95% CI: 
29.0- 32.5%) were either lost to follow-up or died (attrition; 667 children (25.6%; 95% 
CI 24.0-27.3%) were lost-to-follow-up) and 885 (33.9%; 95% CI: 32.1-35.8%) 
transferred out, while the remaining 918 (35.3%; 95% CI: 33.5-37.1%) were alive and in 
care at the end of the first 24-months on ART. When stratified by year, we see an 
increased average age at ART initiation and proportion of female patients initiating ART, 
over time. There is a decrease in the median amount of time on ART over time. The 
proportion of patients with tuberculosis and WHO stage III/IV at ART initiation declined 
slightly over time, while the average CD4 count increased. The high proportion of death, 
attrition and transfers remained consistent over the years. 
Primary outcomes 
 All clinics began phasing out stavudine in accordance with national guidelines in 
2010 (Figure 1). Tenofovir was introduced after WHO recommended its use in first-line 
therapy in 2010; by 2013, <10% of HIV-infected children were initiated on stavudine. 
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While abacavir is included as a first-line NRTI in national guidelines for all patients <14 
years of age, no patients between 3 and 14 were initiated on abacavir post-2010 for first-
line therapy. Over the period of follow-up there were 398 (15.3%; 95% CI: 14.0-16.7%) 
single-drug substitutions; 187 (7.2%; 95% CI: 6.2-8.2%) treatment interruptions and 86 
(3.3%; 95% CI: 2.7-4.0) switches to second-line therapy (Table 2). All outcomes were 
calculated individually in this case. Therefore, 25% of the overall 2602 patients 
experienced a single drug substitution, switch to second-line therapy, or a treatment 
interruption; 75% of patients did not experience a threat to regimen durability in the first 
24 months on treatment. 
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Characteristics 
2004/05 
(n=238) 
n (%) 
2006 
(n=305) 
n (%) 
2007 
(n=334) 
n (%) 
2008 
(n=509) 
n (%) 
2009 
(n=552) 
n (%) 
2010 
(n=371) 
n (%) 
2011 
(n=139) 
n (%) 
2012 
(n=110) 
n (%) 
2013 
(n=44) 
n (%) 
Total 
(n=2602) 
n (%) 
Clinic 
Clinic A 35 (14.7 35 (11.5) 44 (13.2) 52 (10.2) 74 (13.4) 26 (7.0) 17 (12.2) - - 283 (10.9) 
Clinic B 39 (16.4) 68 (22.3) 71 (21.3) 91 (17.9) 81 (14.7) 62 (16.7) 10 (7.2) 14 (12.7) 4 (9.1) 440 (16.9) 
Clinic C   4 (1.7) 5 (1.6) 12 (3.6) 12 (2.4) 29 (5.3) 14 (3.8) 7 (5.0) 5 (4.6) 2 (4.6) 90 (3.5) 
Clinic D  7 (4.1) 4 (1.3) 15 (4.5) 30 (5.9) 40 (7.3) 43 (11.6) 15 (10.8) 15 (13.6) 4 (9.1) 173 (6.7) 
Clinic E  79 (33.2) 83 (27.2) 69 (20.7) 124 (24.4) 113 (20.5) 61 (16.4) 19 (13.7) 16 (14.6) 6 (13.6) 570 (21.9) 
Clinic F  26 (10.9) 57 (18.7) 91 (27.3) 152 (29.9) 154 (27.9) 107 (28.8) 19 (13.7) 9 (8.2) 6 (13.6) 621 (23.9) 
Clinic G  43 (18.1) 37 (12.1) 19 (5.7) 27 (5.3) 27 (4.9) 31 (8.4) 35 (25.2) 34 (30.9) 13 (29.6) 266 (10.2) 
Clinic H  5 (2.1) 16 (5.3) 13 (3.9) 21 (4.1) 34 (6.2) 27 (7.3) 17 (12.2) 17 (15.5) 9 (20.5) 159 (6.1) 
NRTI 
zidovudine  22 (9.2) 18 (5.9) 8 (2.4) 8 (1.6) 7 (1.3) 17 (4.6) 7 (5.0) 14 (12.7) 5 (11.4) 106 (4.1) 
tenofovir  - - - - - 64 (17.3) 99 (71.2) 85 (77.3) 30 (68.2) 278 (10.7) 
stavudine  216 (90.8) 287 (94.1) 326 (97.6) 501 (98.4) 545 (98.7) 290 (78.2) 33 (23.7) 11 (10.0) 9 (20.5) 2218 (85.2) 
NNRTI efavirenz 217 (91.2) 280 (91.8) 308 (92.2) 460 (90.4) 517 (93.7) 330 (89.0) 118 (84.9) 99 (90.0) 39 (88.6) 
2368 
(91.0) 
nevirapine  21 (8.8) 25 (8.2) 26 (7.8) 49 (9.6) 35 (6.3) 41 (11.1) 21 (15.1) 11 (10.0) 5 (11.4) 234 (9.0) 
Age (years) 
3-4.9 42 (17.7) 46 (15.1) 67 (17.1) 95 (18.7) 111 (20.1) 49 (13.2) 6 (4.3) 1 (0.9) 2 (4.6) 409 (15.7) 
5-9.9 125 (52.5) 150 (49.2) 140 (41.9) 219 (43.0) 237 (42.9) 137 (36.9) 8 (5.8) 5 (4.6) 2 (4.6) 1023 (39.3) 
10-13.9 38 (16.0) 48 (15.7) 72 (21.6) 104 (20.4) 102 (18.5) 63 (17.0) 24 (17.3) 11 (10.0) 6 (13.6) 468 (18.0) 
14-19.9 33 (13.9) 61 (20.0) 65 (19.5) 91 (17.9) 102 (18.5) 122 (32.9) 101 (72.7) 93 (84.6) 34 (77.3) 702 (27.0) 
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Characteristics 
2004/05 
(n=238) 
n (%) 
2006 
(n=305) 
n (%) 
2007 
(n=334) 
n (%) 
2008 
(n=509) 
n (%) 
2009 
(n=552) 
n (%) 
2010 
(n=371) 
n (%) 
2011 
(n=139) 
n (%) 
2012 
(n=110) 
n (%) 
2013 
(n=44) 
n (%) 
Total 
(n=2602) 
n (%) 
median 
(IQR) 
8.9  
(5.6-10.7) 
9.5  
(5.8-11.5) 
9.7  
(6.0-12.6) 
9.4  
(5.6-12.1) 
9.4  
(5.5-12.5) 
11.0  
(6.6-16.4) 
15.6  
(13.6-18.9) 
16.7  
(15.5-19.3) 
15.9  
(14.3-18.9) 
10.4  
(6.1-14.5) 
Gender 
female 126 (52.9) 160 (52.5) 178 (53.3) 287 (56.4) 286 (51.8) 200 (53.9) 99 (71.2) 81 (73.6) 32 (72.7) 1448 (55.7) 
male 112 (47.1) 145 (47.5) 156 (46.7) 222 (43.6) 266 (48.2) 171 (46.1) 40 (28.8) 29 (26.4) 12 (27.3) 1153 (44.3) 
CD4 count 
(cells/mm3) 
0-49  29 (12.2) 53 (17.4) 42 (12.6) 75 (14.7) 74 (13.4) 39 (10.5) 22 (15.8) 15 (13.6) 7 (15.9) 356 (13.7) 
50-99 22 (9.2) 13 (4.3) 33 (9.9) 41 (8.1) 40 (7.3) 35 (9.4) 12 (8.6) 6 (5.5) 2 (4.6) 204 (7.8) 
100-199  36 (15.1) 50 (16.4) 59 (17.7) 98 (19.3) 93 (16.9) 56 (15.1) 27 (19.4) 20 (18.2) 7 (15.9) 446 (17.1) 
200-349  44 (18.5) 40 (13.1) 35 (10.5) 79 (15.5) 81 (14.7) 71 (19.1) 33 (23.7) 31 (28.2) 12 (27.3) 426 (16.4) 
>350 45 (18.9) 73 (23.9) 90 (27.0) 146 (28.7) 196 (35.5) 112 (30.2) 21 (15.1) 15 (13.6) 10 (22.7) 708 (27.2) 
missing 62 (26.1) 76 (24.9) 75 (22.5) 70 (13.8) 68 (12.3) 58 (15.6) 24 (17.3) 23 (20.9) 6 (13.6) 356 (13.7) 
median 
(IQR) 
275  
(96-338) 
260  
(52-391) 
307  
(83-418) 
365  
(79-449) 
357.2  
(98-517) 
297.1  
(99-420) 
255.6  
(64-292) 
253  
(88-318) 
329  
(69-387) 
317  
(85-417) 
WHO Stage  
I/II 190 (79.8) 253 (83.0) 275 (82.3) 409 (80.4) 420 (76.1) 304 (81.9) 112 (80.6) 97 (88.2) 39 (88.6) 2099 (80.7) 
III/IV 48 (20.2) 52 (17.1) 59 (17.7) 100 (19.7) 132 (23.9) 67 (18.1) 27 (19.4) 13 (11.8) 5 (11.4) 503 (19.3) 
Tuberculosis  n (%) 16 (6.7) 19 (6.2) 37 (11.1) 51 (10.0) 75 (14.0) 35 (9.4) 13 (9.4) 8 (7.3) 3 (6.8) 257 (9.9) 
Hemoglobin 
(g/dL) 
<10  75 (31.5) 110 (36.1) 109 (32.6) 199 (39.1) 239 (43.3) 162 (43.7) 62 (44.6) 58 (52.7) 26 (59.1) 1040 (40.0) 
>10  56 (23.5) 53 (17.4) 53 (18.9) 100 (19.7) 123 (22.3) 77 (70.8) 32 (23.0) 27 (24.6) 8 (18.2) 529 (20.3) 
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Characteristics 
2004/05 
(n=238) 
n (%) 
2006 
(n=305) 
n (%) 
2007 
(n=334) 
n (%) 
2008 
(n=509) 
n (%) 
2009 
(n=552) 
n (%) 
2010 
(n=371) 
n (%) 
2011 
(n=139) 
n (%) 
2012 
(n=110) 
n (%) 
2013 
(n=44) 
n (%) 
Total 
(n=2602) 
n (%) 
missing 107 (45.0) 142 (46.6) 172 (51.5) 210 (41.3) 190 (34.4) 132 (35.6) 45 (32.4) 25 (22.7) 10 (22.7) 1033 (39.7) 
median 
(IQR) 
10.3  
(9.1-11.2) 
10.5  
(9.6-11.7) 
10.6  
(9.5-11.9) 
11.6  
(9.6-11.6) 
10.6  
(9.6-11.5) 
10.6  
(9.6-11.8) 
10.9  
(9.0-12.4) 
11.2  
(9.6-12.8) 
11.1  
(10.1-13.0) 
10.8  
(9.5-11.7) 
Body Mass 
Index (kg/m2) 
median 
(IQR) 
11.8  
(8.2-15.0) 
14.2 
(10.3-
16.9) 
13.3  
(9.5-16.3) 
14.0 
(11.5-
16.8) 
14.7 
(11.5-
16.8) 
15.4 
(12.2-
17.2) 
19.9 
(15.8-
21.1) 
21.3 
(17.7-
23.5) 
20.2  
(16.2-22.7) 
15.0 
(11.0-
17.6) 
Time on ART 
(months) 
median 
(IQR) 
24.0 
(22.5-
24.0) 
24.0 
(16.9-
24.0) 
24.0 
(17.4-
24.0) 
23.6 
(14.7-
24.0) 
21.4 
(11.3-
24.0) 
20.2  
(8.7-24.0) 
20.2  
(7.3-24.0) 
13.6  
(7.0-24.0) 
16.2  
(6.8-24.0) 
23.4 
(12.6-
24.0) 
Vital status over 24-months 
of follow-up           
Alive  n (%) 85 (35.7) 104 (34.1) 116 (34.7) 173 (34.0) 185 (33.5) 136  (36.7) 48 (34.5) 47 (42.7) 24 (54.6) 
918 
(35.3) 
Death n (%) 15 (6.3) 17 (6.6) 20 (6.0) 28 (5.5) 26 (4.7) 16 (4.3) 3 (2.2) 5 (4.6) 2 (4.6) 132 (5.1) 
Loss to follow-
up n (%) 71 (29.8) 75 (24.6) 80 (24.0) 108 (21.2) 146 (26.5) 97 (26.2) 47 (33.8) 31 (28.2) 12 (27.3) 
667 
(25.6) 
Transfers n (%) 63 (26.5) 105 (34.4) 117 (35.0) 197 (38.7) 195 (35.3) 122 (32.9) 41 (29.5) 27 (24.6) 6 (13.6) 873 (33.6) 
Primary outcome over 24-months of follow-up  
Single-drug    
substitution n (%) 3 (1.3) 22 (7.2) 39 (11.7) 81 (15.9) 125 (22.6) 95 (25.6) 17 (12.2) 10 (9.1) 6 (13.6) 
398 
(15.3) 
Treatment 
interruption n (%) 15 (6.3) 19 (6.2) 14 (4.2) 47 (9.2) 44 (8.0) 30 (8.1) 10 (7.2) 5 (4.6) 3 (6.8) 187 (7.2) 
Second-line 
Switch  n (%) 11 (4.6) 11 (3.6) 10 (3.0) 15 (3.0) 16 (2.9) 13 (3.5) 6 (4.3) 1 (0.9) 3 (6.8) 86 (3.3) 
 
Table 2. Clinical and demographic characteristics at ART initiation and outcomes at 24-months of follow-up stratified by year 
initiated onto treatment at eight RTC Clinics, Johannesburg, South Africa (n=2602) 
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Figure 1. Trends in the use of stavudine in first-line ART for HIV-infected patients <20 
years of age at initiation in South Africa 
 
 
 
Single-drug substitution 
 Overall, the frequency of single-drug substitutions over 24 months on ART 
started to increase for the cohort of patients that started treatment in 2009, peaked in 2011 
at 25%, and then declined to 10% in 2013 (Figure 2). When stratifying outcomes by age 
and year of treatment initiation, decreases in single-drug substitutions in patients <14 
years of age begins two years after the 2010 change in the national guidelines (Figure 4a). 
Of note, while abacavir is included as a first-line NRTI in national guidelines for all 
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patients <14 years of age, no patients between the ages of 3 and 14 were initiated on 
abacavir post-2010 for first-line therapy. All clinics followed national guidelines 
regarding antiretrovirals eligible for substitution in the NRTI drug class (stavudine, 
didanosine or zidovudine). These included tenofovir, stavudine, zidovudine or abacavir, 
depending on the NRTI included in the first-line regimen, with the occasional use of 
didanosine as an alternative (Figure 3). Of the 398 single-drug substitutions, abacavir was 
frequently used for stavudine substitution (14.3%; 95% CI: 12.9-15.8%), while tenofovir 
was the choice for zidovudine substitution (10.4%; 95% CI: 5.6-17.3%). Patients on 
tenofovir were predominately switched to zidovudine (4.3%; 95% CI: 2.4-7.2%). Models 
show that patients initiated on stavudine or zidovudine had a 4- and 5-fold, respectively, 
increase in the hazards of single-drug substitutions over the period of follow-up 
compared to tenofovir (Table 3). Consistent with known toxicity patterns, single-drug 
substitutions occurred earlier for patients on tenofovir (median 5.4 months after start of 
treatment IQR: 3.0-17.1), while substitutions of patients on zidovudine occurred at a 
median of 18.0 months (IQR: 7.1-21.7) and those on stavudine occurred at a median 20.2 
months (IQR: 15.9-22.5) after start of treatment. When stratified by age, median time on 
ART prior to single-drug substitution is comparable for all age groups. 
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Figure 2. Trends in single-drug substitution, treatment interruption and second-line 
switching over 24-months on ART stratified by year of ART initiation HIV-infected 
patients <20 years of age in South Africa 
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Figure 3. Proportion of patients with an NRTI single-drug substitution and the substituting 
NRTI in the first 24-months on treatment stratified by initial NRTI in first-line ART in 
HIV-infected children and adolescents in South Africa (N=398) 
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Treatment interruption 
 Treatment interruption over 24 months on ART peaked at 8% in 2009 and 
declined to 5% in 2013. Duration of treatment interruption was comparable between 
patients on tenofovir (4.1 months; IQR: 1.1-7.7) and zidovudine (4.9 months; IQR: 2.4-
8.5), while patients on stavudine had a shorter median time of interruption (3.0 months; 
IQR: 1.0-8.4). When stratified by age, median time on ART prior to treatment 
interruption is comparable for the younger age groups at around 23 months (IQR: 12.6-
24.0), while patients >14 had a shorter duration on ART prior to interruption (16.6 
months; IQR: 9.6-23.9). Median time on ART prior to treatment interruption was 
comparable between tenofovir (4.1 months; 95% CI: 1.1-7.7) and zidovudine (4.9 
months; IQR: 2.4-8.5), while patients on stavudine had a shorter duration (3.0 months; 
IQR: 1.0-8.4). Regression results showed patients initiated on stavudine had a 130% 
increase in the hazards of treatment interruption when compared to those on tenofovir, 
while those on zidovudine had a 60% decrease. 
 
Second-line switch 
 Second-line switches remained consistent at 3.3% (95% CI: 2.7-4.0%) over 24 
months on ART over time. Time from ART initiation to second-line switch was 
comparable between all three NRTIs (tenofovir, stavudine, zidovudine) (20.5 months; 
IQR: 15.9-22.2). When stratified by age, there is comparable median time on ART prior 
to second-line switching in patients <14 years of age (21.0 months; IQR: 15.9-22.7), 
while patients >14 years old had a median of 18.5 months (IQR: 15.9-21.3). The majority 
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(62.8%; 95% CI: 52.2-72.5%) of patients experiencing a second-line switch initiated a 
second-line regimen comprised of zidovudine/lamivudine/lopinavir+ritonavir. Patients 
that were on stavudine or zidovudine compared to tenofovir had a 1.5 to 2-fold increase 
in the hazards of switching to second-line ART over the time period. 
 
Hazard Ratios 
Our results also suggest that children 14 to 20 years of age have an increased hazard of 
all three primary outcomes compared to patients 5 to 9.9 years of age (single-drug 
substitution – HR 1.6; 95%CI: 0.9-2.8; treatment interruption – HR 2.3; 95%CI: 1.4-3.8; 
and second-line switch – HR 3.7; 95%CI:1.2-11.2) (Figure 4, Table 3). Since we believed 
changes in the trends of substitutions, treatment interruptions, and second-line switching 
for sex and age (<10 vs. >10 years) could vary by NRTI used in first-line ART, we 
calculated the risk due to interdependence(R(I)). We showed a positive interdependence 
for gender and stavudine use in first-line ART for all three primary outcomes (single-
drug substitution: 6.4%; treatment interruption:  10% and second-line switches: 5.6%). 
Therefore, 6.4% of single-drug substitutions in female patients on stavudine is related to 
the dual action of female gender and stavudine. The risk of single-drug substitution in 
doubly exposed patients (females exposed to stavudine) was 13.2% vs. the risk of 6.7%% 
in the doubly unexposed (males unexposed to stavudine). The risk of treatment 
interruption in the doubly exposed was 9.3% vs. the risk of -0.7% in the doubly 
unexposed, while the risk of second-line switching in the doubly exposed was 0.3% vs. 
the risk of -5.3% in the doubly unexposed. We did not see any signs of interaction when 
  
18 
assessing the biological relationships between age and use of stavudine using the R(I). 
 
Figure 4. Trends in single-drug substitution (a), treatment interruption (b) and second-line 
switching (c) over 24-months on ART stratified by year and age at ART initiation in HIV-
infected patients <20 years of age in South Africa 
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*The model is clustered by site and adjusted for non-nucleoside reverse transcriptase inhibitor, body mass index, hemoglobin and World Health 
Organization stage. 
 
Table 3. Model adjusted for predictors of single-drug substitution, treatment interruption and second-line switch for children and 
adolescents in the first 24-months on ART in Johannesburg, South Africa (n=2602) 
  Single-drug substitution Treatment interruption Second-line switch 
Variable Events (%) Adjusted HR* (95% CI) Events (%) 
Adjusted 
HR* 
(95% CI) 
Events (%) Adjusted HR* (95% CI) 
       
NRTI       
 tenofovir 8 (2.9) Reference 18 (6.5) Reference 13 (4.7) Reference 
 zidovudine 15 (14.2) 5.3 (1.6-17.3) 4 (3.8) 0.4 (0.1-1.3) 5 (4.7) 2.0 (0.3-11.5) 
 stavudine 375 (16.9)  4.2 (1.6-11.0) 165 (7.4) 2.3 (1.1-4.7) 68 (3.1) 1.4 (0.5-4.4) 
Age (years)        
 3-4.9 68 (16.6) 1.0 (0.7-1.7) 26 (6.4) 1.1 (0.6-2.2) 8 (2.0) 1.2 (0.3-3.8) 
 5-9.9 180 (17.6) Reference 62 (6.1) Reference 19 (1.9) Reference 
 10-13.9 82 (17.5) 1.5 (1.0-2.3) 29 (6.2) 0.8 (0.4-1.5) 19 (4.1) 2.0 (0.8-5.0) 
 14-19.9 68 (9.7) 1.4 (0.8-2.4) 70 (10.0) 2.0 (1.1-3.7) 40 (5.7) 3.3 (1.1-10.0) 
Sex        
 Male 177 (15.4) Reference 86 (7.5) Reference 33 (2.9) Reference 
 Female   221 (15.3) 1.1 (0.8-1.4) 101 (7.0) 1.0 (0.6-1.4) 53 (3.7) 1.2 (0.6-2.3) 
CD4 count (cells/mm3)       
 >350 53 (14.9) Reference 25 (7.0) Reference 20 (2.8) Reference 
 200-349 62 (13.7) 1.1 (0.7-1.7) 20 (9.8) 1.2 (0.7-2.3) 9 (2.1) 0.9 (0.3-2.5) 
 100-199 56 (12.6) 0.8 (0.5-1.3) 42 (9.4) 1.3 (0.7-2.4) 14 (3.1) 1.1 (0.4-3.0) 
 50-99 28 (14.6) 0.9 (0.5-1.6) 31 (7.3) 1.4 (0.7-2.8) 9 (4.4) 0.9 (0.3-3.1) 
 0-49 53 (21.2) 0.9 (0.5-1.4) 43 (6.1) 1.2 (0.6-2.3) 18 (5.1) 1.6 (0.6-4.3) 
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CHAPTER FOUR: DISCUSSION 
 Published reports on treatment outcomes in pediatric patients with HIV are 
limited. This analysis provides data regarding first-line regimen durability of children 
initiated on ART in South Africa during ART programmatic changes to include both 
tenofovir and abacavir as NRTIs in first-line pediatric regimens.  These data show there is 
overall compliance to the post-2010 guidelines, with a majority of children initiated on an 
appropriate ART regimen according to age, though no children <14 were initiated on an 
abacavir-containing regimen as first-line therapy.  The single-drug substitution peak seen 
roughly 2 years post-2010 is likely a result of clinicians switching treatment-experienced 
pediatric patients from stavudine to either abacavir or tenofovir, as age-appropriate. That 
the peak of these guideline-congruent single-drug substitutions in patients younger <14 
years of age begins two years after the national guidelines changes (Figure 4a) may be 
due to clinics prioritizing tenofovir in first-line regimens for adults before focusing on 
tenofovir for children.  
 The decline in both single-drug substitutions and treatment interruptions after 
2010 may be a result of fewer side-effects and toxicities in those children initiated on 
tenofovir as per 2010 guidelines, but this does not fully account for the decrease in 
treatment interruptions seen since 2006 (pre-dating the  guideline change).  The 
proportion of switches to second-line regimens has not changed over time. While it is 
reassuring that with increased use of abacavir (in this population, after a single-drug 
substitution) and tenofovir, there has not been an increase in switches to second-line 
therapy, switches to second-line have not decreased. The introduction of first-line 
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regimens including abacavir or tenofovir with a better tolerated side-effect profile, and 
therefore potentially increased adherence, might be expected to be associated with 
decreased switches to second-line. Given that adherence challenges in pediatric 
populations are multifactorial and due at least in part to family structure and caregiver 
ability and knowledge, improved side effect profiles are only one component of 
adherence to ART for children. However, it is important to note that overall in this 
cohort, regardless of initiating NRTI, 75% of patients did not experience either a single 
drug substitution, treatment interruption, or switch to second-line therapy.  
 This is the first study in pediatric patients to examine single-drug substitutions, 
treatment interruptions, and switches to second-line therapy, though previous adult 
studies reported increased hazards of single-drug substitutions when comparing stavudine 
to tenofovir (9-15). We similarly found increased hazards of single-drug substitution 
when comparing both stavudine and zidovudine to tenofovir, adjusting for choice of 
NNRTI, BMI, WHO clinical staging and hemoglobin at time of initiation. Stavudine was 
also associated with increased hazards for treatment interruption compared to tenofovir. 
The oldest pediatric patients had increased hazards of all outcomes (though single-drug 
substitution was not significant), and female patients had a trend toward increased 
hazards for all outcomes. This is consistent with previous research in adults, which 
demonstrated increase risk of single drug substitution for females and higher risk of 
toxicity/side effects for women on stavudine (13,14,15,16,22,23).  Differences in risk of 
toxicity between genders, and therefore increased risk of single drug substitution, may be 
related to better adherence in women than men (24, 25). There is a paucity of literature on 
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adherence patterns in adolescents, with most studies dependent on self-reported ART 
adherence in adolescent populations (26, 27, 28), and therefore it is difficult to fully 
explain why female adolescent patients in this study had increased risk compared to male 
adolescents. The unique developmental changes in adolescence characterized by 
increased-risk taking behavior and decreased impulse control (29), at a time when 
adolescent patients may still need adherence support from family/caregivers, can 
adversely impact adolescent ART adherence. There is no available data on differences in 
adherence for male and female adolescents.  
 There are several limitations to this analysis. Reasons for single-drug 
substitutions, switches to second-line, and treatment interruptions are unknown in this 
dataset, and limit inferences regarding associations. Treatment interruptions for this 
analysis were defined using prescription data for all patients. If the time between stopping 
an ART regimen and resuming an ART regimen was >1 week, then the patient was 
defined as having a treatment interruption event. As the prescription data is hand-entered 
by a clinician or data entry clerk, it is possible that human error results in incorrect 
regimen dates. However, we don’t anticipate the rate of this outcome misclassification to 
be differential by initiating NRTI, and therefore, any bias in our estimates of risk of 
treatment interruption would be towards the null. Another limitation is lack of knowledge 
of children’s exposure to PMTCT, and the degree to which different PMTCT regimens 
may have influenced regimen durability, particularly for younger children. Importantly, 
the overall numbers of children under 3 years old in this cohort were limited (data not 
shown) and were excluded given the complexity of first-line therapy regimens for very 
  
23 
young children recently exposed to PMTCT regimens. Additionally, there was a high rate 
of loss to follow-up and attrition in this cohort, similar to other pediatric studies. 
 Though there are significant limitations, a clear strength is the large numbers of 
HIV-infected children included in the analysis, and the fact that these children received 
care at large ART clinics without specialist pediatric care. This increases the 
generalizability of these results, as this represents “real world” conditions for many HIV-
infected children in resource-limited settings. In this population of children receiving care 
in public clinics, over time, the median age of patients initiating ART increased, from 8.9 
years old in 2004 to 15.9 years old in 2011.  It is unknown if HIV diagnosis in these 
children was delayed from presumed perinatal transmission, or alternatively in older 
adolescents, represents infection post-natally. We are limited by the lack of knowledge 
regarding mode of transmission for all children included in this study. It does seem likely 
that older ages at initiation may be secondary to problems with linkages to care and ART 
initiation. In addition to older ages at time of ART initiation, we demonstrated that 
median time on ART decreased over time. Given that the proportion of death, attrition 
and transfers remained consistent over the years, it is unclear why this trend was noted 
over time.  
 Overall, this study shows that regimen durability in the first two years after ART 
initiation appears to have improved after introduction of tenofovir, with decline of both 
single-drug substitution and treatment interruptions, though no changes in switches to 
second-line therapy.  The decrease in single-drug substitution was delayed in younger 
patients compared to older adolescents, and is hypothesized to reflect a delay in initiation 
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of tenofovir for younger patients with prioritization of tenofovir for adult (and older 
adolescent) patients.  Stavudine and zidovudine, when compared to tenofovir, were 
associated with increased hazards of all outcomes. While better side-effect profiles with 
tenofovir-containing regiments for pediatric patients might be assumed to result in 
increased adherence and therefore less need for switch to second-line, it is well-known 
that adherence for children and adolescents is multifactorial and dependent largely on 
caregivers’ participation, which may be one factor for the overall decreased median time 
on ART over time in this cohort. Therefore, while the use of appropriate and efficacious 
first-line ART since 2010 has been demonstrated to have good uptake in South Africa for 
pediatric patients with decreasing trends of threats to regimen durability, further work on 
improving the adherence of all pediatric patients, especially adolescent patients, is 
crucial.  
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APPENDIX 
*Interaction was assessed at p<0.20 
€The model is clustered by site and adjusted for CD4 count, age, non-nucleoside reverse transcriptase inhibitor, body mass index, hemoglobin and 
World Health Organization stage at ART initiation. 
 
Table 4. Adjusted models assessing the interaction between age at ART initiation and use of stavudine in first-line ART for 
children and adolescents in the first 24-months on ART in Johannesburg, South Africa (n=2602) 
 Single-drug substitution Treatment interruption Second-line switch 
Variable 
Crude HR 
(95% CI) 
Adjusted HR* 
(95% CI) 
Crude HR 
(95% CI) 
Adjusted HR* 
(95% CI) 
Crude HR 
(95% CI) 
Adjusted HR* 
(95% CI) 
Age       
3-4.9|stavudine 1.6 (0.6-4.4) 1.5 (0.4-4.9) 2.5 (0.3-18.3) 2.6 (0.4-19.2) 0.6 (0.1-4.7) 0.4 (0.1-4.9) 
5-9.9|stavudine Reference Reference Reference Reference Reference Reference 
10-13.9|stavudine   1.8 (0.7-4.9) 2.1 (0.6-6.7) 2.5 (0.3-18.5) 2.4 (0.3-17.5) 1.6 (0.2-11.9) 1.0 (0.1-7.7) 
14-19.9|stavudine 1.6 (0.6-4.4) 1.7 (0.5-5.9) 5.6 (0.8-40.6)* 5.1 (0.7-37.1)* 2.9 (0.4-21.6) 1.7 (0.2-14.5) 
Gender       
male|stavudine Reference Reference Reference Reference Reference Reference 
female|stavudine 1.9 (1.0-3.4) 1.8 (0.9-3.8)* 1.0 (0.5-1.9) 2.0 (0.8-5.1)* 0.4 (0.2-0.9)* 0.9 (0.3-2.2) 
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